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Abstract
Background: Data on lipid profile derangements induced by antiretroviral treatment in Africa are scarce. The aim of this
study was to determine the prevalence and characteristics of lipid profile derangements associated with first-line highly
active antiretroviral therapy (ART) among Cameroonians living with human immunodeficiency virus (HIV) infection.
Methods: This cross-sectional study was conducted between November 2009 and January 2010, and involved 138
HIV patients who had never received ART (ART-naive group) and 138 others treated for at least 12 months with
first line triple ART regimens that included nevirapine or efavirenz (ART group). Lipid profile was determined after
overnight fast and dyslipidemia diagnosed according to the US National Cholesterol Education Program III criteria.
Data comparison used chi-square test, Student t-test and logistic regressions.
Results: The prevalence of total cholesterol ≥ 200 mg/dl was 37.6% and 24.6% respectively in ART group and ART-
naive groups (p = 0.019). The equivalents for LDL-cholesterol ≥ 130 mg/dl were 46.4% and 21% (p ≤ 0.001). Proportions
of patients with total cholesterol/HDL-cholesterol ratio ≥ 5 was 35.5% in ART group and 18.6% in ART-naive group (p ≤
0.001). The distribution of HDL-cholesterol and triglycerides was similar between the two groups. In multivariable
analysis adjusted for age, sex, body mass index, CD4 count and co-infection with tuberculosis, being on ART was
significantly and positively associated with raised total cholesterol, LDL-cholesterol and TC/HDL cholesterol. The
adjusted odd ratios (95% confidence interval, p-value) ART-treated vs. ART-naïve was 1.82 (1.06-1.12, p = 0.02) for TC ≥
200 mg/dl; 2.99 (1.74-5.15), p < 0.0001) for LDL-cholesterol ≥ 130 mg/dl and 1.73 (1.04-2.89, p = 0.03) for TC/HDL-
cholesterol ≥ 5.
Conclusions: First-line antiretroviral therapy that includes nonnucleoside reverse transcriptase inhibitors is
associated with pro-atherogenic adverse lipid profile in people with HIV-1 infection compared to untreated HIV-
infected subjects in Yaounde. Lipid profile and other cardiovascular risk factors should be monitored in patients on
such therapy so that any untoward effects of treatments can be optimally managed.
Keywords: antiretroviral therapy, dyslipidemia, HIV, Cameroon
Introduction
The advent of highly active antiretroviral therapy
(HAART) has modified the natural history of human
immunodeficiency virus (HIV) infection through reduc-
tion in risks of death associated with the condition and
improvement of the quality of life of people living with
the infection [1,2]. However, antiretroviral drugs also
have side effects of varying order of severity. Derange-
ments of lipid metabolism associated with HAART have
been largely characterised in the West and in several
developing countries, particularly in patients on treat-
ment regimens including protease inhibitors (PIs) and
stavudine [3,4], but also for treatment regimens including
nevirapine and efavirenz [5,6]. Antiretroviral therapy
(ART) can induce raised levels of total cholesterol (TC),
LDL-cholesterol (LDL-c) and triglycerides (TG), and
variables effects on HDL-cholesterol (HDL-c) levels [4].
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atherogenic and can increase cardiovascular risk [7,8].
First-line HAART regimens as defined by the World
Health Organisation (WHO) and that are largely used in
resources-constrained countries do not include PIs
[9,10]. Evidences in support of lipid profile derangements
associated with HAART in sub-Saharan Africa are scarce
[11,12]. The aim of the present study was to determine
the prevalence and determinants of derangements in
lipid profile associated with the use of first-line ART regi-
mens in Cameroonians with HIV infection.
Participants and Methods
Study setting and Participants
This was a cross-sectional study. Participants were
recruited between November 2009 and January 2010 at
the registered treatment centre of the Yaounde Jamot’s
Hospital. Two groups of participants were selected. One
group included individuals with HIV-1 infection and who
had been receiving ART for at least 12 months, based on
WHO first-line regimens (ART group). First-line ART
regimens applied to these participants were those that
included lamivudine (3TC), stavudine (d4T) or zidovudine
(AZT), and nevirapine (NVP) or efavirenz (EFV). The
choice of regimens was unrelated to potential factors that
could induce a dyslipidemia, given that lipid profile assess-
ment is not part of routine pre-ART treatment evaluation
in this setting [9]. Patients who had had their treatment
regimens changed during follow-up were excluded. The
second group was made up of individuals newly diagnosed
with HIV-1 infection and who were not yet receiving ART
(ART-naïve group). Participants had to be at least 18 years
of age and to have a treatment adherence rate ≥ 95% (for
the treated group). Level of adherence was assessed by ver-
bal administration of a standard series of questions
adapted from Adult AIDS clinical trials group (AACTG)
adherence instruments. The 95% rate of adherence is
referable to 4-day recall data [13]. Participants were also
required not to be on lipid modifying therapies at their
enrolment. All participants gave their inform consent and
the study was approved by the Cameroon National Ethic
Committee (ref N°150/CNE/SE/09).
Methods
For each participant, data were collected on the sociode-
mographic background, past medical history including the
use of medications that could modify the lipid profile and
active or history of tuberculosis. ART-naïve participants
were screened for HIV-1 and HIV-2 infection with the use
of a rapid test (DETERMINE HIV 1-2, Abbott, Tokyo,
Japan). Those whose’ screening test was positive had their
status confirmed with a 3
rd generation immunochromato-
graphic test (HEXAGON HIV, Human Laboratory, Wies-
baden, Germany). Lymphocytes count for all participants
used flux cytometry methods implemented with BD
FASCOUNT automate (BD Biosciences, Le pont de Claix,
France). Lipid profile was assessed through enzymatic
methods (Linear chemicals, Montgat, Spain) for all
patients and included total cholesterol (TC), HDL-choles-
terol (HDL-c), LDL-cholesterol (LDL-c) and triglycerides
(TG). To this end, blood sample was collected after an
overnight fast (12 hours) and centrifuged at 3000 cycles/
minute, and the serum obtained was then used for lipids
determination. The TC/HDL-c ratio was also calculated.
In accordance with the US National Cholesterol Education
Program, Adult Treatment Panel III (NCEP-ATP III)
guidelines, abnormal lipid profile was defined as TC ≥ 200
mg/dl, HDL-c < 40 mg/dl, LDL-c ≥ 130 mg/dl, TG ≥ 150
mg/dl and TC/HDL-c ratio ≥ 5 [14].
Statistical analysis
Sample size was determined assuming a 5% prevalence of
total cholesterol > 200 mg/dl in patients ART-naïve
patient, a minimum detectable unadjusted odds ratio (OR)
of 2, a Type I error of 5% and a power of 80% [11]. Based
on the above, the required sample size was 268 partici-
pants (134 ART-naïve and 134 ART-treated patients).
Data analysis used Statical package for social sciences
(SPSS) version 17 for Windows (SPSS, Chicago, IL).
Differences in means and proportions for participants’
characteristics were assessed using Student t-test and c
2
tests and variants as applicable, and the influence of likely
confounders adjusted for through logistic regressions
models. Potential predictors consider for inclusion in
models were those found to be correlated with lipid
abnormalities during ART elsewhere [11,15]. A probability
threshold of P < 0.05 was set as the threshold of statistical
significance.
Results
Characteristics of the study population
In all, 138 participants on ART and 138 ART-naïve parti-
cipants were included. Sixty-eight (49.3%) patients in the
ART-naïve group had active tuberculosis and 55 (39.6%)
in the ART group had had tuberculosis prior to been
started on ART. Meanwhile, no patient in the ART group
had active tuberculosis at inclusion in the study. First-line
ART regimens were as followed: d4T/3TC/NVP (61 parti-
cipants), d4T/3TC/EFV (32 participants), AZT/3TC/NVP
(31 participants) and AZT/3TC/EFV (14 participants).
Therefore among ART patients, 93 (64.4%) participants
were on d4T, 45 (32.6%) on AZT, 92 (66.7%) on NVP and
46 (33.3%) on EFV. All regimens included 3TC. ART
patients had been on treatment for an average of 30
months (standard deviation: 13). The profile of partici-
pants is described in Table 1. There was no significant dif-
ference between the ART group and ART-naive group for
age (40.6 vs. 38.7 years, p = 0.07), sex distribution (% men:
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Page 2 of 834.8% vs. 43.5%, p = 0.139) and origin (% urban: 90.6% vs.
92.8%, p = 0.51). ART participants were more likely to
have high body mass index (p = 0.001) and high CD4 lym-
phocytes count (p = 0.016).
Lipid profile and first-line ART treatment
Mean TC and mean LDL-c were higher in patients on
ART than in ART-naïve patients (both p < 0.02). There
was no significant difference between the two groups for
HDL-c and triglycerides (Table 2). The prevalence of
lipid profiles abnormalities is depicted in Table 3. The
prevalence of TC ≥ 200 mg/dl was 37.7% among ART
group and 24.6% in the ART-naïve group (p = 0.013).
The equivalents for LDL-c ≥ 130 mg/dl were 46.4% and
21%, p < 0.001; and those for TC/HDL-c ratio ≥ 5 were
35.5% among patients on ART and 18.6% among ART-
naïve patients (p < 0.001).
In multivariable analysis adjusted for age, sex, body mass
index, CD4 count and co-infection with tuberculosis, being
on ART was significantly and positively associated with
raised total cholesterol, LDL-cholesterol and TC/HDL
cholesterol. The adjusted odd ratios (95% confidence inter-
val, p-value) ART-treated vs. ART-naïve was 1.82 (1.06-
1.12, p = 0.02) for TC ≥ 200 mg/dl; 2.99 (1.74-5.15), p <
0.0001) for LDL-cholesterol ≥ 130 mg/dl and 1.73 (1.04-
2.89, p = 0.03) for TC/HDL-cholesterol ≥ 5 (Table 4).
Univariable and multivariable logistic regressions
models were also used to investigate independent deter-
minants of lipid derangements in the subgroup on ART
alone. In both univariable and multivariable analyses,
body mass index was the main determinant of raised
LDL-c in ART-treated patients (Table 5).
Lipid abnormalities and ART regimens
Figures 1 and 2 show the prevalence of lipid abnormal-
ities according to ART regimens. There was no signifi-
cant difference in the prevalence of lipid abnormalities
in patients on regimens that included d4T as compared
with those on regimens that included AZT. The preva-
lence of lipid abnormalities induced by nevirapine and
efavirenz was also similar in patients on ART.
Discussion
The aim of this study conducted in a resource-poor setting
was to assess the prevalence of, and characterise lipid
abnormalities associated with the use of first-line ART
regimens that include nonnucleoside reverse transcriptase
inhibitors (NNRTIs). We found that patients on first-line
ART had high levels of total cholesterol, LDL-c and high
TC/HDL-c ratio as compared with ART-naïve patients.
Serum levels of HDL-c and triglycerides were similar
between HIV-infected untreated patients and HIV-
infected patients on ART. The described derangements
Table 1 Profile of 138 ART-naïve and 138 first-line ART treated individuals in Yaounde, Cameroon
Characteristics First-line ART-treated
(n = 138)
ART-naïve
(n = 138)
p
Men, n (%) 48 (34.8) 60 (43.5) 0.139
Residence, urban, n (%) 125 (90.6) 128 (92.8) 0.513
Mean age, years (SD) 40.6 (8.7) 38.7 (8.7) 0.069
Mean BMI, kg/m
2 (SD) 24.6 (4.7) 23.0 (3.6) 0.001
Median CD4 lymphocytes count, per mm
3
(IQR)
333
(206-459.3)
274.5
(159-408.3)
0.016
Mean duration on ART, months (SD)
Active tuberculosis
Past history of tuberculosis
30.2 (13.1)
0
55(39.6)
NA
68 (49.3)
0
NA
NA
NA
ART, antiretroviral therapy; BMI, body mass index; SD, standard deviation; NA, not applicable; IQR, interquartile range.
Table 2 Value of different lipid parameters between first-
line ART group and ART-naïve group in Yaounde,
Cameroon
Lipid parameter First-line
ART treated
(n = 138)
ART-naïve
(n = 138)
p
Total cholesterol, mg/dl 196 (91) 172 (73) 0.018
HDL cholesterol, mg/dl 49 (26) 49 (25) 0.944
LDL cholesterol, mg/dl 133 (89) 100 (68) 0.001
Triglycerides, median, mg/dl (IQR) 134 (98-174) 134 (111-170) 0.331
TC/HDL-cholesterol ratio 5.0 (3.0) 4.3 (3.5) 0.091
Data are mean values (± standard deviation) unless otherwise indicated. ART,
antiretroviral therapy; TC, total cholesterol; IQR, interquartile range.
Table 3 Prevalence of abnormal lipid levels among first-
line ART-treated patients and ART-naïve patients in
Yaounde, Cameroon
Lipid parameter First-line
ART-treated
n = 138(%)
ART-naïve
n = 138(%)
p
Total cholesterol ≥ 200 mg/dl 52 (37.7) 33 (24.6) 0.013
HDL cholesterol < 40 mg/dl 55 (39.9) 51 (37.0) 0.620
LDL cholesterol ≥ 130 mg/dl 64 (46.4) 29 (21.0) < 0.001
Triglycerides ≥ 150 mg/dl 60 (43.5) 53 (38.4) 0.392
TC/HDL cholesterol ratio ≥ 5 49 (35.5) 19 (13.8) < 0.001
ART, antiretroviral therapy; TC, total cholesterol.
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Cameroon
Outcome variables Explanatory variables Adjusted OR
(95% CI)
P
TC ≥ 200 (mg/dl) Antiretroviral therapy 1.82 (1.06-3.12) 0.02
Sex (Women vs. Men) 0.83 (0.48-1.43) 0.49
Age > 40 years 1.27 (0.74-2.17) 0.39
BMI > 25 kg/m
2 1.05 (0.59-1.86) 0.87
Active tuberculosis 0.49 (0.28-0.86) 0.01
CD4 count ≤ 200/mm
3 2.56 (0.34-20.00) 0.36
LDL-c ≥ 130 (md/dl) Antiretroviral therapy 2.99 (1.74-5.15) < 0.0001
Sex (Women vs. Men) 1.06 (0.61-1.82) 0.84
Age > 40 years 1.13 (0.66-1.94) 0.65
BMI > 25 kg/m
2 1.87 (1.07-3.27) 0.02
Active tuberculosis 0.54 (0.31-0.95) 0.03
CD4 count ≤ 200/mm
3 1.92 (0.24-15.74) 0.54
TC/HDL-c ratio ≥ 5 Antiretroviral therapy 1.73 (1.04-2.89) 0.03
Sex (Women vs. Men) 1.88 (1.11-3.20) 0.02
Age > 40 years 1.49 (0.89-2.50) 0.20
BMI > 25 kg/m
2 0.68 (0.40-1.17) 0.16
Active tuberculosis 1.12 (0.67-1.89) 0.68
CD4 count ≤ 200/mm
3 1.78 (0.22-14.43) 0.59
BMI, body mass index; OR, odds ratio; CI, confidence interval; LDL-c, LDL cholesterol;
TC, total cholesterol; HDL-c, HDL cholesterol.
Table 5 Determinants of abnormal lipid profile in 138 first-line ART treated individuals in Yaounde, Cameroon
Outcome variables Explanatory variables OR p
a Ajusted OR p
b
(95%CI) (95% CI)
TC ≥ 200 (mg/dl) Sex (Women vs. Men) 0.99 (0.48-2.04) 0.99 0.96 (0.45-2.03) 0.93
Age > 40 years 1.38 (0.69-2.76) 0.36 1.41 (0.69-2.91) 0.35
BMI > 25 kg/m
2 1.22 (0.59-2.52) 0.59 1.06 (0.49-2.29) 0.88
Treatment duration > 2 years 2.07 (1.03-4.17) 0.04 2.08 (1.01-4.27) 0.05
d4T vs. AZT regimen 0.75 (0.36-1.56) 0.44 0.78 (0.32-1.81) 0.55
NVP vs. EFV regimen 0.79 (0.26-2.41) 0.67 0.79 (0.21-2.99) 0.73
Past history of tuberculosis 0.80 (0.39-1.62) 0.54 0.85 (0.41-1.80) 0.68
LDL-c ≥ 130 (md/dl) Sex (Women vs. Men) 0.70 (0.33-1,51) 0.32 0.67 (0.32-1.40) 0.29
Age > 40 years 0.74 (0.36-1.54) 0.38 0.57 (0.28-1.18) 0.23
BMI > 25 kg/m
2 2.23 (1.04-4.80) 0.02 2.65 (1.24-5.68) 0.01
Treatment duration > 2 years 0.93 (0.45-1.93) 0.83 0.87 (0.42-1.80) 0.71
d4T vs. AZT regimen 1.73 (0.79-3.78) 0.13 1.71 (0.72-4.06) 0.22
NVP vs. EFV regimen 1.18 (0.34-4.01) 0.77 0.99 (0.26-3.72) 0.98
Past history of tuberculosis 1.54 (0.73-3.25) 0.22 1.72 (0.89-3.62) 0.15
TC/HDL-c ratio ≥ 5 Sex (Women vs. Men) 1.79 (0.79-4.14) 0.13 1.61 (0.73-3.54) 0.23
Age > 40 years 0.67 (0.31-1.43) 0.26 0.72 (0.34-1.50) 0.38
BMI > 25 kg/m
2 0.99 (0.45-2.16) 0.97 0.88 (0.41-1.89) 0.74
Treatment duration > 2 years 1.93 (0.60-2.97) 0.08 1.90 (0.89-4.06) 0.1
d4T vs. AZT regimen 1.33 (0.60-2.97) 0.44 1.56 (0.66-3.73) 0.31
NVP vs. EFV regimen 1.01 (0.27-3.58) 1 0.68 (0.17-2.65) 0.58
Past history of tuberculosis 0.72 (0.34-1.56) 0.37 0.77 (0.37-1.63) 0.5
BMI, body mass index; OR, odds ratio; CI, confidence interval; LDL-c, LDL cholesterol; TC, total cholesterol; HDL-c, HDL cholesterol; p
a, p value for unadjusted odds
ratio; p
b, p value for adjusted odds ratio
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after adjustment for potential confounders.
The association between HAART and adverse lipid pro-
file has been largely described for regimens that include
protease inhibitors (PIs) [4,16-19]. It is well known that
PIs and NNRTIs induce derangements of lipid profile dur-
ing ART [3-5,17,20]. However, evidence in support of the
adverse effects of NNRTIs on lipid profile of HIV treated
patients in sub-Saharan Africa are very limited [11,12].
The proportion of patients with high total cholesterol
among our ART treated participant was similar to that
reported by Zannou et al in the cohort in Benin [12], but
higher than the rate found in rural Ugandans [11]. These
two studies were cohort studies wherein participants were
followed for a 24 months period for the onset of lipid
derangements. However, there are suggestions that the
magnitude of first-line ART induced lipid derangements
could vary across populations and settings. Cross-sectional
studies from other resources-constrained settings have
reported prevalence of high level of total cholesterol
ranging from 23 to 41% in patients treated with NNRTI-
based regimens [15,21]. Based on LDL-c cut-points, we
found a prevalence of dyslipidemia that was higher than
that reported in Uganda [11] and in India [15]. Prevalence
rates in these two studies were respectively 6% and 30%.
Similarly, in these two studies the prevalence of high LDL-
c prior to ART was also lower than that found in our
study (≤ 4% vs. 21%). The HDL-c and triglycerides levels
were unaffected by first-line HAART in our study is not in
accordance with the findings of Pujari and his colleagues
in India [15]. In this study, an 18-month treatment with
first-line ART regimens was associated with significant
increase in HDL-c and triglycerides.
Several studies have found that stavudine was more
involved in the occurrence of lipid derangements as com-
pared with other NRTIs [22,23]. We found no difference
in lipid profiles when participants on stavudine were com-
pared to those on zidovudine. This is in line with the find-
ings of Buchacz et al in Uganda [11], and those of Pujari et
al in India [15]. The two NNRTIs included in the WHO
first-line regimens are nevirapine and efavirenz. Two stu-
dies have found that patients treated with nevirapine had a
better lipid profile than those treated with efavirenz
[24,25]. In accordance with Buchacz et al [11], we found
no difference in the lipid profile of patients on nevirapine
compared with those on efavirenz. In our study, high
LDL-c was associated with ART use, but also with body
mass index, including in the subgroup only on ART. The
Figure 1 Prevalence of lipid abnormalities in patients treated with stavudine (left vertical bars) and those treated with zidovudine
(right vertical bars). ■ Stavudine-based regimen (n = 93). ▩ Zidovudine-based regimen (n = 45). TC, total cholesterol; HDL-c, HDL-cholesterol;
LDL-c, LDL-cholesterol; TG, Triglycerides.
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It is therefore possible that our findings reflect more these
well known lipid derangements associated with obesity
than sides effects of ART.
Our study did not assess the global cardiovascular risk of
participants. However, the increased risk of atherothom-
botic cardiovascular disease associated with the described
lipid derangement is well know [4,5,7,8,27] and would
therefore suggest that treatment with first-line ART may
actually have harmful effects on the cardiovascular health
of our population. Our study, by nature is cross-sectional
and inference about causal relationship is not possible.
Cohorts’ studies would be indicated to monitor lipid pro-
file alterations during first-line ART, and their potential
impact on cardiovascular health of people living with HIV
in our settings. The other limitation of our study is the
lack of HIV-negative controls. In fact untreated HIV infec-
tion is associated with low LDL-c and low HDL-c [28],
particularly in those patients with severe immune-depres-
sion [29]. It is therefore possible that high levels of LDL-c
found in our study actually just reflect a “catch-up phe-
nomenon”. However, the higher median CD4 count in our
HIV-naive subgroup would tend to suggest that they were
less likely to have severe immune-depression type lipid
profile [29]. In this context, their lipid profile is likely clo-
ser to that in the general population without HIV infec-
tion. This would also minimise limitations relating to the
lack of a non HIV infected control subgroup.
Conclusion
In conclusion, WHO first-line HAART with regimens
that include NNRTIs are associated with potentially
atherogenic adverse lipid profile in patients with HIV-1
infection compared to untreated HIV-infected patients
in our setting. This may indicate the need to update the
current recommendations of WHO pertaining to biolo-
gical monitoring of patients on first-line antiretroviral
therapy to include lipid panel. Lipid profile and other
cardiovascular risk factors should be monitored in
patients on such therapy so that any untoward effects of
ART can be optimally managed.
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